Eris Lifesciences Announces Interim Dividend and Shares FY 2026 Financial Results
Eris Lifesciences Limited announced the outcome of its Board Meeting held on May 20, 2026, confirming the audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. Furthermore, the Board declared an interim dividend for the financial year 2026-2027.Dividend Declaration and Key Dates
During the meeting, the Board of Directors of Eris Lifesciences Limited declared an interim dividend of Rs 7.21/- (at a rate of 721%) on each fully paid-up equity share of Re 1/- each for the Financial Year 2026-2027.The company set the record date for determining the eligibility of shareholders for the dividend payment as Friday, May 29, 2026. The payment of the interim dividend is scheduled to be made on or before June 19, 2026.
Financial Results Highlights (FY 2026 vs FY 2025)
The company released audited consolidated and standalone financials, showing revenue growth and varied profitability trends year over year.Consolidated Financial Performance
For the Group as a whole, the Total Income for the year ended March 31, 2026, stood at 3,137.17 Rs in Crore, up from 2,912.00 Rs in Crore recorded in the previous fiscal year. Net profit for the period was 647.51 Rs in Crore, compared to 374.67 Rs in Crore in March 31, 2025.
| Metric (Rs in Crore) | March 31, 2026 (Audited) | March 31, 2025 (Audited) |
|---|---|---|
| Total Income | 3,137.17 | 2,912.00 |
| Total Expenses | 2,481.48 | 2,423.19 |
| Net Profit for the Period | 647.51 | 374.67 |
| Total Comprehensive Income | 646.07 | 371.38 |
Standalone Financial Performance
The standalone financials reflected a Total Income of 1,920.05 Rs in Crore for the year ended March 31, 2026. The net profit for the period stood at 244.05 Rs in Crore, a significant jump from 77.39 Rs in Crore reported in March 31, 2025.
| Metric (Rs in Crore) | March 31, 2026 (Audited) | March 31, 2025 (Audited) |
|---|---|---|
| Total Income | 1,920.05 | 1,733.26 |
| Total Expenses | 1,543.33 | 1,613.21 |
| Net Profit for the Period | 244.05 | 77.39 |
| Total Comprehensive Income | 244.74 | 74.55 |
Balance Sheets (As at March 31, 2026)
The Balance Sheets provide a clear comparison of the company's assets and liabilities structure.| Particulars | March 31, 2026 (Audited) | March 31, 2025 (Audited) |
|---|---|---|
| TOTAL ASSETS | 7,365.51 | 7,036.41 |
| Property, plant and equipment | 661.52 | 604.89 |
| Goodwill | 911.97 | 911.97 |
| Other intangible assets | 3,567.22 | 3,732.44 |
| Total Non-current assets | 5,825.66 | 5,810.18 |
| Total Current assets | 1,539.85 | 1,226.23 |
| TOTAL EQUITY AND LIABILITIES | 7,365.51 | 7,036.41 |
| Total Equity | 3,895.66 | 3,271.76 |
| Non-current liabilities | 1,392.75 | 2,380.02 |
| Current liabilities | 2,077.10 | 1,384.63 |
Cash Flow Summary
The cash flow statement highlights the company's operational and financing activities.| Activity | March 31, 2026 (Audited) | March 31, 2025 (Audited) |
|---|---|---|
| Net cash from operating activities (A) | 537.99 | 1,065.01 |
| Net cash used in investing activities (B) | (694.16) | (358.99) |
| Net cash flow from financing activities (C) | (313.53) | (881.32) |
| Net increase/(decrease) in cash and cash equivalents (A+B+C) | 199.74 | 103.72 |
Additional Information
The company reported that, under the Standalone financials, the profit before tax for the period was 362.05 Rs in Crore, derived from a total income of 1,920.05 Rs in Crore. For the Consolidated financials, the profit before tax was 638.54 Rs in Crore, based on a total income of 3,137.17 Rs in Crore.***
Note: Financial figures are presented as reported in the source material, with units specified in Rs in Crore where applicable.
ERIS Stock Price Movement
Shares of Eris Lifesciences Limited are edging higher to ₹1428.6 as of 3:07 PM today, rallying 6.92% in live trading. The equity is trading on significant activity, with 269,446 shares changing hands during the active market session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: